Cargando…

Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study

The association between coronavirus disease 2019 (COVID-19) pneumonia and venous thrombotic disorders is still unclear. We assessed the association between COVID-19 infection-related pneumonia and proximal deep-vein thrombosis (DVT) in a cohort of patients admitted to our hospital during the Europea...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgi-Pierfranceschi, Matteo, Paoletti, Oriana, Pan, Angelo, De Gennaro, Fabio, Nardecchia, Anna Laura, Morandini, Rossella, Dellanoce, Claudia, Lombi, Samuele, Tala, Maurizio, Cancelli, Vanessa, Zambelli, Silvia, Bosio, Giancarlo, Romanini, Laura, Testa, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445816/
https://www.ncbi.nlm.nih.gov/pubmed/32840805
http://dx.doi.org/10.1007/s11739-020-02472-3
_version_ 1783574056130314240
author Giorgi-Pierfranceschi, Matteo
Paoletti, Oriana
Pan, Angelo
De Gennaro, Fabio
Nardecchia, Anna Laura
Morandini, Rossella
Dellanoce, Claudia
Lombi, Samuele
Tala, Maurizio
Cancelli, Vanessa
Zambelli, Silvia
Bosio, Giancarlo
Romanini, Laura
Testa, Sophie
author_facet Giorgi-Pierfranceschi, Matteo
Paoletti, Oriana
Pan, Angelo
De Gennaro, Fabio
Nardecchia, Anna Laura
Morandini, Rossella
Dellanoce, Claudia
Lombi, Samuele
Tala, Maurizio
Cancelli, Vanessa
Zambelli, Silvia
Bosio, Giancarlo
Romanini, Laura
Testa, Sophie
author_sort Giorgi-Pierfranceschi, Matteo
collection PubMed
description The association between coronavirus disease 2019 (COVID-19) pneumonia and venous thrombotic disorders is still unclear. We assessed the association between COVID-19 infection-related pneumonia and proximal deep-vein thrombosis (DVT) in a cohort of patients admitted to our hospital during the European outbreak in the front line of Cremona, Lombardy. In a single-center cross-sectional study, all patients hospitalized for more than 5 days in Internal Medicine Department with confirmed COVID-19 pneumonia received 2-point compressive ultrasound assessment (CUS) of the leg vein system during a single day. Ninety-four percent of patients received enoxaparin as standard pharmacological prophylaxis for venous thromboembolism. The presence of DVT was defined as incompressibility of popliteal or common femoral vein. Out of 121 patients with COVID-19 pneumonia (mean age 71.8, 66.3% males) hospitalized on March 31st, 70 stayed in hospital for over 5 days and 66 of them underwent CUS of deep venous system of the legs. The presence of asymptomatic DVT was found in 9 patients (13.6%). No symptomatic DVT was found. Patients with DVT showed mean age = 75.7 years, mean D-dimer levels = 4.02 ng/ml and all of them received enoxaparin for thromboprophylaxis, except one. Computed tomography pulmonary angiogram confirmed pulmonary embolism in five patients. One every seven patients with COVID-19-related pneumonia, hospitalized for more than 5 days, had asymptomatic proximal DVT and half of them had confirmed PE despite standard pharmacological thromboprophylaxis. This observational study suggests the need of an active surveillance through CUS in patients hospitalized with acute SARS-COV-2 and underline the need of a more intense thromboprophylaxis.
format Online
Article
Text
id pubmed-7445816
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74458162020-08-26 Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study Giorgi-Pierfranceschi, Matteo Paoletti, Oriana Pan, Angelo De Gennaro, Fabio Nardecchia, Anna Laura Morandini, Rossella Dellanoce, Claudia Lombi, Samuele Tala, Maurizio Cancelli, Vanessa Zambelli, Silvia Bosio, Giancarlo Romanini, Laura Testa, Sophie Intern Emerg Med Im - Original The association between coronavirus disease 2019 (COVID-19) pneumonia and venous thrombotic disorders is still unclear. We assessed the association between COVID-19 infection-related pneumonia and proximal deep-vein thrombosis (DVT) in a cohort of patients admitted to our hospital during the European outbreak in the front line of Cremona, Lombardy. In a single-center cross-sectional study, all patients hospitalized for more than 5 days in Internal Medicine Department with confirmed COVID-19 pneumonia received 2-point compressive ultrasound assessment (CUS) of the leg vein system during a single day. Ninety-four percent of patients received enoxaparin as standard pharmacological prophylaxis for venous thromboembolism. The presence of DVT was defined as incompressibility of popliteal or common femoral vein. Out of 121 patients with COVID-19 pneumonia (mean age 71.8, 66.3% males) hospitalized on March 31st, 70 stayed in hospital for over 5 days and 66 of them underwent CUS of deep venous system of the legs. The presence of asymptomatic DVT was found in 9 patients (13.6%). No symptomatic DVT was found. Patients with DVT showed mean age = 75.7 years, mean D-dimer levels = 4.02 ng/ml and all of them received enoxaparin for thromboprophylaxis, except one. Computed tomography pulmonary angiogram confirmed pulmonary embolism in five patients. One every seven patients with COVID-19-related pneumonia, hospitalized for more than 5 days, had asymptomatic proximal DVT and half of them had confirmed PE despite standard pharmacological thromboprophylaxis. This observational study suggests the need of an active surveillance through CUS in patients hospitalized with acute SARS-COV-2 and underline the need of a more intense thromboprophylaxis. Springer International Publishing 2020-08-25 2020 /pmc/articles/PMC7445816/ /pubmed/32840805 http://dx.doi.org/10.1007/s11739-020-02472-3 Text en © Società Italiana di Medicina Interna (SIMI) 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Im - Original
Giorgi-Pierfranceschi, Matteo
Paoletti, Oriana
Pan, Angelo
De Gennaro, Fabio
Nardecchia, Anna Laura
Morandini, Rossella
Dellanoce, Claudia
Lombi, Samuele
Tala, Maurizio
Cancelli, Vanessa
Zambelli, Silvia
Bosio, Giancarlo
Romanini, Laura
Testa, Sophie
Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
title Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
title_full Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
title_fullStr Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
title_full_unstemmed Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
title_short Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
title_sort prevalence of asymptomatic deep vein thrombosis in patients hospitalized with sars-cov-2 pneumonia: a cross-sectional study
topic Im - Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445816/
https://www.ncbi.nlm.nih.gov/pubmed/32840805
http://dx.doi.org/10.1007/s11739-020-02472-3
work_keys_str_mv AT giorgipierfranceschimatteo prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT paolettioriana prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT panangelo prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT degennarofabio prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT nardecchiaannalaura prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT morandinirossella prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT dellanoceclaudia prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT lombisamuele prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT talamaurizio prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT cancellivanessa prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT zambellisilvia prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT bosiogiancarlo prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT romaninilaura prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy
AT testasophie prevalenceofasymptomaticdeepveinthrombosisinpatientshospitalizedwithsarscov2pneumoniaacrosssectionalstudy